Fig. 5.

GW405833 dose dependently reversed CFA-induced mechanical allodynia in WT but not in CB₁KO mice (A). The antiallodynic effect of GW405833 (30 mg/kg i.p.) in WT mice was completely blocked by the CB₁ antagonist rimonabant (10 mg/kg i.p.) (B) Mechanical withdrawal thresholds in the contralateral paw were not changed by CFA injection or treatments (B). WT (CD1), n = 8 males; CB₁KO, n = 6 males. ^#P < 0.05 vs. baseline; *P < 0.05 vs. vehicle (0 mg/kg i.p.); ^P < 0.05 vs. GW405833 (3 mg/kg i.p.); ^$P < 0.05 vs. GW405833 (10 mg/kg i.p.); ⁺P < 0.05 vs. CB₁KO; ^&P < 0.05 versus GW405833 (30 mg/kg i.p.) in WT. BL, preinjection baseline; ipsilateral, injected paw; contralateral, uninjected paw.